James R. Kasinger

General CounselatCRISPR Therapeutics AG· In proxies 2021–2025

Pay in FY2025-53% from the year before · CRISPR Therapeutics AG stock +33.2% the same year

James R. Kasinger was paid $2.9M in FY2025 (Dec), down 53%. CRISPR Therapeutics AG stock rose 33.2% that year.

Pay$100 in the stock at the end of FY20 → $34

Pay is from the Summary Compensation Table of each CRISPR Therapeutics AG proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

CRISPR Therapeutics AGPublic company · 5 yr
- General Counsel2021 – Present · 5 yrStock in role -68%

Roles come from the proxy statements of each company.

Activity

Pay
CRISPR Therapeutics AG General counsel pay fell 53% to $2.9M. The stock rose 33% in FY2025 (Dec).
DEF 14AApr 21, 2026
Pay
CRISPR Therapeutics AG General counsel pay rose 74% to $6.1M. The stock fell 37% in FY2024 (Dec).
DEF 14AApr 16, 2025
Pay
CRISPR Therapeutics AG General counsel pay fell 29% to $3.5M. The stock rose 54% in FY2023 (Dec).
DEF 14AApr 9, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?